Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Imatinib|DRUG: Docetaxel
Sponsor: SCRI Development Innovations, LLC
Collaborators: Novartis|Aventis Pharmaceuticals